AstraZeneca hit by falling Crestor sales, higher costs

Reuters: Company News Reuters: Company News

LONDON, May 18 (Reuters) - Generic competition to cholesterol fighter Crestor and higher costs hit AstraZeneca in the first quarter, despite good sales of new drugs, but the group said on Friday it remained on track for a promised return to sales growth in 2018.

Reuters: Company News

Leave a Reply